Integrated in Silico Docking and MOMA SimulationMethods Reveal Rottlerin as a Potent Janus kinase 2(JAK2) Inhibitor

@inproceedings{Vadapalli2018IntegratedIS,
  title={Integrated in Silico Docking and MOMA SimulationMethods Reveal Rottlerin as a Potent Janus kinase 2(JAK2) Inhibitor},
  author={Jyothirmayi Vadapalli and Anuradha Vanam and Noboru Motohashi and Rao Gollapudi and Xiaoyong Yang and Junhua Wang and Leilei Chen and Jiying Qiu and Donfrancesco Cristina and Piccioni Maria Grazia and Perniola Giorgia and Muzii Ludovico and Benedetti Panici Pierluigi},
  year={2018}
}
Janus kinase 2 (JAK2) is a prospective drug target for myeloproliferative neoplasms, mainly polycythemia Vera, essential thrombocythemia and primary myelofibrosis disorders. JAK2 abnormalities are mainly identified in myeloid neoplasms. Multiple type I ATP-competitive JAK inhibitors with various specificities displayed potent anti-inflammatory activity with minimum hematologic toxicity in clinical trials. Therefore, only two tyrosine kinase inhibitors have been approved by Food and Drug… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Mechanism of activation of protein kinase JAK2 by the growth hormone receptor

AJ Brooks, W Dai, ML O Mara, D Abankwa, Y Chhabra
  • Science
  • 2014

Molecular docking mutational studies on human surfactant protein-D

L Nousheen, PC Akkiraju, S Enaganti
  • World J Pharmaceut Res,
  • 2014
VIEW 1 EXCERPT